Methods and compositions involving immunostimulatory oligodeoxynucleotides
View Patent ↗Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any NMP is a 2′ deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2′ deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 150, B and E are common groups for 5′ or 3′ ends of nucleic acid molecules, as well as a pharmaceutical composition containing such ODNs.
1. A method of production of a pharmaceutical composition comprising combining at least one antigen and at least one immunostimulatory oligodeoxynucleotide molecule (ODN) consisting of the sequence oligo-dIC 26-mer (SEQ ID NO:30), wherein the pharmaceutical composition is further defined as comprising 10 ng to 1 mg of the ODN.
2. The method of production according to claim 1 , wherein the pharmaceutical composition further comprises at least one of a polycationic polymer, an antimicrobial peptide, a growth hormone, a cytokine, an anti-inflammatory substance, a pharmaceutically acceptable carrier, a buffer substance or a stabilizer.
3. The method of production according to claim 1 , wherein the at least one antigen is derived from viral or bacterial pathogens, from fungi or parasites, and/or wherein the antigens are tumor antigens or autoimmune disease antigens.
4. The method of production according to claim 2 , wherein the polycationic polymer is a synthetic peptide comprising two KLK-motifs separated by a linker of 3 to 7 hydrophobic amino acids.